EUVIMEDEUVIMED entdecken
Crossref

Fatty Liver Index as an Upstream Marker of Glycaemic and Cardiometabolic Dysregulation Preceding MASLD : Evidence From Two Longitudinal Cohorts

Hongmei Zhang, Yifan Hu, Jiajie Cai, Ning Zhang, Yuan Zhang, Yi Xiang, Jianqin Zhong, Qiong Meng, Qiang Tan, Xufang Gao, Zhuoga Ciren, Xiong Xiao iD und 1 weitere

Diabetes, Obesity and Metabolism · 2026

DOI: 10.1111/dom.70851 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes, Obesity and Metabolism, 2026. Verfasst von Hongmei Zhang und 12 weiteren Autor:innen. Beteiligte Einrichtung: West China School of Public Health and West China Fourth Hospital, Sichuan University, Chengdu, China. Hauptthemen laut MEDLINE: Blood Glucose, Fatty Liver, Cardiovascular Diseases, Non-alcoholic Fatty Liver Disease. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 63 Literaturangaben. Gefördert von: the National Natural Science Foundation of China, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Metabolic dysfunction–associated fatty liver disease (MASLD) is reversible in the preclinical metabolic stage. However, the temporal interactions between hepatic steatosis and cardiometabolic abnormalities remain poorly understood. Research Design and Methods This longitudinal study included 4186 participants from the China Multi‐Ethnic Cohort (CMEC) and 2620 participants from the UK Biobank (UKB) with data available at both baseline and follow‐up. Hepatic steatosis was assessed using the Fatty Liver Index (FLI). Cardiometabolic risk factors, including blood pressure, blood glucose and lipid profiles, were measured at both time points. Cross‐lagged panel network analysis was applied to construct temporal networks linking hepatic steatosis and cardiometabolic factors. Centrality metrics, including out‐expected influence (Out‐EI), in‐expected influence (In‐EI), and bridge‐expected influence (Bridge‐EI), were used to identify key nodes within the networks.

Results

Across both cohorts, pathways from baseline FLI to subsequent blood pressure and blood glucose predominated over reverse pathways ( β FLI → SBP = 0.079 versus β SBP → FLI = 0.016; β FLI → FBG = 0.056 versus β FBG → FLI = 0.022 in CMEC, and β FLI → SBP = 0.046 versus β SBP → FLI = 0.000; β FLI → FBG = 0.018 versus β FBG → FLI = −0.005 in UKB), suggesting that hepatic steatosis was more strongly associated with subsequent elevations in these cardiometabolic factors during the preclinical metabolic stage of MASLD. Centrality analyses indicated that FLI occupied a relatively upstream and central position within the temporal network, with consistently high Out‐EI and Bridge‐EI in both CMEC and UKB (FLI Out‐EI = 0.344 and Bridge‐EI = 0.344 in CMEC; Out‐EI = 0.209 and Bridge‐EI = 0.209 in UKB). In contrast, Fasting Blood Glucose (FBG) primarily functioned as a downstream affected node, exhibiting higher In‐EI (FBG In‐EI = 0.189 in CMEC; 0.159 in UKB).

Conclusions

FLI emerged as an upstream and central marker of metabolic dysregulation in the preclinical metabolic stage of MASLD, whereas FBG appeared to represent a downstream manifestation. Our findings clarify the temporal dynamics of metabolic dysregulation in this stage and highlight FLI as a potential priority marker for early screening.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Blood GlucoseFatty LiverCardiovascular DiseasesNon-alcoholic Fatty Liver DiseaseHumansLongitudinal StudiesFemaleMaleMiddle AgedBiomarkersCardiometabolic Risk FactorsUnited KingdomChinaAdultBlood PressureUK BiobankCohort StudiesRisk Factors

Stichwörter der Autor:innen

cardiovascular metabolic risk factorsglycaemichepatic steatosisnetwork analysis

Substanzen

Blood GlucoseBiomarkers

Autor:innen und Institutionen

  • West China School of Public Health and West China Fourth Hospital, Sichuan University, Chengdu, China.
  • Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China.
  • School of Public Health, Key Laboratory of Environmental Pollution Monitoring and Disease Control, Ministry of Education, Guizhou Medical University, Guiyang, China.
  • School of Public Health, Kunming Medical University, Kunming, China.
  • Chongqing Center for Disease Control and Prevention, Chongqing, China.
  • Chengdu Center for Disease Control and Prevention, Chengdu, China.

ORCID-Profile: Xiong Xiao, Xing Zhao

Förderung

  • the National Natural Science Foundation of China
  • National Natural Science Foundation of China

Zitieren

APA

Zhang, H., Hu, Y., Cai, J., Zhang, N., Zhang, Y., Xiang, Y., Zhong, J., Meng, Q., Tan, Q., Gao, X., Ciren, Z., Xiao, X., & Zhao, X. (2026). Fatty Liver Index as an Upstream Marker of Glycaemic and Cardiometabolic Dysregulation Preceding MASLD : Evidence From Two Longitudinal Cohorts. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.70851

Vancouver

Zhang H, Hu Y, Cai J, Zhang N, Zhang Y, Xiang Y, et al. Fatty Liver Index as an Upstream Marker of Glycaemic and Cardiometabolic Dysregulation Preceding MASLD : Evidence From Two Longitudinal Cohorts. Diabetes, Obesity and Metabolism. 2026. doi:10.1111/dom.70851

BibTeX
@article{Zhang2026,
  author = {Zhang, Hongmei and Hu, Yifan and Cai, Jiajie and Zhang, Ning and Zhang, Yuan and Xiang, Yi and Zhong, Jianqin and Meng, Qiong and Tan, Qiang and Gao, Xufang and Ciren, Zhuoga and Xiao, Xiong and Zhao, Xing},
  title = {Fatty Liver Index as an Upstream Marker of Glycaemic and Cardiometabolic Dysregulation Preceding MASLD : Evidence From Two Longitudinal Cohorts},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2026},
  doi = {10.1111/dom.70851}
}
Kostenlos starten →